Skip to Main Content (Press Enter)

Logo UNISS
  • ×
  • Home
  • Degrees
  • Courses
  • Jobs
  • People
  • Outputs
  • Organizations
  • Third Mission
  • Expertise & Skills

Logo UNISS

|

UNIFIND

uniss.it
  • ×
  • Home
  • Degrees
  • Courses
  • Jobs
  • People
  • Outputs
  • Organizations
  • Third Mission
  • Expertise & Skills
  1. Outputs

Impact of universal vaccination against varicella in Italy: Experiences from eight Italian Regions

Academic Article
Publication Date:
2015
Short description:
Impact of universal vaccination against varicella in Italy: Experiences from eight Italian Regions / Bechini, A; Boccalini, S; Baldo, V; Cocchio, S; Castiglia, Paolo Giuseppino; Gallo, T; Giuffrida, S; Locuratolo, F; Tafuri, S; Martinelli, D; Prato, R; Amodio, E; Vitale, F; Bonanni, P.. - In: HUMAN VACCINES & IMMUNOTHERAPEUTICS. - ISSN 2164-554X. - 11:1(2015), pp. 63-71. [10.4161/hv.34311]
abstract:
In Italy, the introduction of Universal Varicella Vaccination (UVV) has been decided but postponed, as a national programme, until 2015, when data from Regions which have already implemented it will be available. Starting from 2003, eight Italian Regions (Basilicata, Calabria, Friuli Venezia Giulia, Apulia, Sardinia, Sicily, Tuscany and Veneto) have progressively introduced UVV, in their immunization programme, with different schedules in children aged 13-15 months and 5-6 years, currently a two-dose schedule is adopted by all Regions. In June 2013, an Interregional Group on Varicella Vaccination (IGVV) has been established in order to assess the effectiveness of varicella vaccination with standardized and shared tools. The aim of this study was to evaluate the impact of varicella vaccination on the incidence and hospitalizations due to varicella and its complications in the period 2003-2012 in order to support the Italian decision makers on the future national adoption. Preliminary data showed that a general reduction of incidence and hospitalization rates was observed in the study period, resulting in relevant savings for the National Health Service. Immunization coverage with first dose at 24 months of age was high in all Regions (84%-95%) in 2012. Adverse events due to varicella vaccines were rare and without permanent sequelae. Underreporting of varicella cases and delays in the administration of the first dose of varicella vaccines were the main critical issues. In conclusion, solid evidences in support of universal UVV arise from the experiences available today in Italy.
Iris type:
1.1 Articolo in rivista
List of contributors:
Bechini, A; Boccalini, S; Baldo, V; Cocchio, S; Castiglia, Paolo Giuseppino; Gallo, T; Giuffrida, S; Locuratolo, F; Tafuri, S; Martinelli, D; Prato, R; Amodio, E; Vitale, F; Bonanni, P.
Authors of the University:
CASTIGLIA Paolo Giuseppino
Handle:
https://iris.uniss.it/handle/11388/47751
Published in:
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Journal
  • Overview

Overview

URL

https://www.tandfonline.com/doi/full/10.4161/hv.34311
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.5.1.0